MI Cancer Seek

North Texas’ Caris Life Sciences Eyes $5.3B Valuation in Its Nasdaq IPO

by | Jun 10, 2025
The Irving-based leader in precision oncology—which has raised $1.86 billion since 2018—plans to raise as much as $423.5 million when it goes public on the Nasdaq Global Select Market under the ticker symbol CAI.
MORE
North Texas’ Caris Life Sciences Gets FDA Approval for its ‘MI Cancer Seek’ Companion Diagnostic Test
by | Nov 6, 2024
Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
MORE